International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report)’s share price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.17 and traded as high as $0.2999. International Stem Cell shares last traded at $0.2999, with a volume of 7,300 shares.
International Stem Cell Stock Performance
The firm’s fifty day moving average is $0.20 and its 200-day moving average is $0.17. The company has a market capitalization of $2.40 million, a P/E ratio of -5.00 and a beta of -0.03.
International Stem Cell (OTCMKTS:ISCO – Get Free Report) last announced its earnings results on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $2.32 million during the quarter.
International Stem Cell Company Profile
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
See Also
- Five stocks we like better than International Stem Cell
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
